抗球蟲藥物市場 - 按藥物類別、藥物作用、動物類型、配銷通路、地區和競爭細分的全球行業規模、佔有率、趨勢、機會和預測，2019-2029F

2023 年全球抗球蟲藥物市場價值為13.4 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為3.86%。發展的領域，全球對畜產品的需求不斷成長，以及家禽、牛、豬和其他動物球蟲病的持續威脅。球蟲病是由艾美耳屬原生動物寄生蟲引起的，由於生產力、發病率和死亡率的降低，給畜牧業帶來了重大的經濟損失。因此，在集約化養殖方式的日益採用、對食品安全和動物福利的日益關注以及球蟲抗藥性菌株的出現的推動下，抗球蟲藥物市場出現了大幅成長。市場主要參與者繼續投資於研發活動，以推出具有更高功效、安全性以及與各種生產系統相容性的新型配方。

市場概況
預測期	2025-2029
2023 年市場規模	13.4億美元
2029 年市場規模	16.5億美元
2024-2029 年複合年成長率	3.86%
成長最快的細分市場	伴侶動物
最大的市場	北美洲

生物技術和分子生物學的進步促進了疫苗、益生菌和球蟲病控制酶等替代策略的開發，加劇了市場內的競爭。從地理上看，北美和歐洲由於畜牧養殖場高度集中、動物健康監管嚴格以及研發投資龐大，在全球抗球蟲藥物市場佔據主導地位。然而，在畜牧業擴張、可支配收入增加以及人們對動物生產中預防性醫療措施益處的認知不斷提高的推動下，亞太地區預計在未來幾年將出現顯著成長。此外，持續的COVID-19大流行凸顯了畜牧業生物安全和疾病預防的重要性，從而增加了對抗球蟲藥和其他獸藥的需求。

監管限制、對抗菌素抗藥性的擔憂以及向有機和永續農業實踐的轉變對市場成長構成了挑戰。在技​​術進步、不斷變化的消費者偏好以及在競爭日益激烈的農業環境中提高動物健康和生產力的持續需求的推動下，全球抗球蟲藥物市場將持續擴張。

主要市場促進因素

對畜牧產品的需求不斷增加

球蟲病患病率上升

藥物開發的技術進步

主要市場挑戰

監管限制

對抗菌素抗藥性的擔憂

抗球蟲藥物的新興替代品

主要市場趨勢

在全球推廣集約化農業實踐

關注動物健康與福利

細分市場洞察

藥品類別見解

藥物行動見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球抗球蟲藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依藥物類別（離子載體、抗生素、磺胺類、化學衍生物、其他藥物類別）
  • 透過藥物作用（抑制球蟲、殺球蟲）
  • 依動物類型（生產動物、伴侶動物）
  • 按配銷通路（獸醫院、零售藥局、其他分銷管道）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按地區

第 6 章：亞太地區抗球蟲藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲抗球蟲藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美抗球蟲藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 9 章：南美洲抗球蟲藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲抗球蟲藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 透過藥物作用
  • 依動物類型
  • 按配銷通路
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：全球抗球蟲藥市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• Vetoquinol SA
• Zoetis Philippines Inc
• Phibro Animal Health Corporation
• Huvepharma, Inc
• Elanco US Inc.
• Biochem Pharmaceutical Industries Ltd
• Ceva Sante Animale SA
• Impextraco NV
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global Anticoccidial Drugs Market was valued at USD 1.34 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.86% through 2029. The global anticoccidial drugs market is a dynamic and rapidly evolving sector within the animal health industry, driven by the escalating demand for livestock products worldwide and the persistent threat of coccidiosis in poultry, cattle, swine, and other animals. Coccidiosis, caused by protozoan parasites of the genus Eimeria, poses significant economic losses to the livestock industry due to reduced productivity, morbidity, and mortality rates. As a result, the market for anticoccidial drugs has witnessed substantial growth, propelled by the increasing adoption of intensive farming practices, rising concerns over food safety and animal welfare, and the emergence of drug-resistant strains of coccidia. Key players in the market continue to invest in research and development activities to introduce novel formulations with improved efficacy, safety profiles, and compatibility with various production systems.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.34 Billion
Market Size 2029	USD 1.65 Billion
CAGR 2024-2029	3.86%
Fastest Growing Segment	Companion Animals
Largest Market	North America

Advancements in biotechnology and molecular biology have facilitated the development of alternative strategies such as vaccines, probiotics, and enzymes for coccidiosis control, thereby intensifying competition within the market. Geographically, North America and Europe dominate the global anticoccidial drugs market owing to the high concentration of livestock farms, stringent regulations governing animal health, and substantial investments in research and development. However, Asia-Pacific is anticipated to witness significant growth in the coming years, driven by the expansion of the livestock sector, increasing disposable incomes, and growing awareness regarding the benefits of preventive healthcare measures in animal production. Moreover, the ongoing COVID-19 pandemic has underscored the importance of biosecurity and disease prevention in livestock farming, thereby accentuating the demand for anticoccidial drugs and other veterinary pharmaceuticals.

The regulatory constraints, concerns over antimicrobial resistance, and the shift towards organic and sustainable farming practices pose challenges to market growth. The global anticoccidial drugs market is poised for continued expansion, fueled by technological advancements, evolving consumer preferences, and the persistent need to enhance animal health and productivity in an increasingly competitive agricultural landscape.

Key Market Drivers

Escalating Demand for Livestock Products

The escalating demand for livestock products is a significant factor driving the growth of the global anticoccidial drugs market. As the world's population continues to grow, so does the demand for animal-derived products such as meat, dairy, and eggs. This increasing demand has led to the expansion of intensive farming practices, where large numbers of animals are raised in confined spaces to meet the growing need for protein-rich food sources.

The intensification of livestock production also brings with it challenges, including a higher risk of disease outbreaks such as coccidiosis. Coccidiosis is a parasitic disease caused by protozoan parasites of the genus Eimeria, which infect the intestinal tract of poultry, cattle, swine, and other animals, leading to reduced productivity and economic losses for farmers.

To meet the rising demand for livestock products while mitigating the risks posed by diseases like coccidiosis, farmers increasingly rely on anticoccidial drugs to protect the health and productivity of their animals. These drugs work by controlling the growth and spread of coccidia in the intestines, thereby reducing the severity of the disease and its impact on livestock performance.

The growing awareness among farmers about the importance of disease prevention and biosecurity measures has further fueled the demand for anticoccidial drugs. Farmers recognize the need to safeguard their animals against diseases that can compromise their health and productivity, and anticoccidial drugs offer an effective means of achieving this goal.

The intensification of livestock production has led to a greater emphasis on maximizing efficiency and profitability. Anticoccidial drugs play a crucial role in achieving these objectives by helping to maintain optimal growth rates, feed conversion ratios, and overall performance in livestock. By controlling coccidiosis and reducing the incidence of disease-related losses, these drugs enable farmers to achieve higher yields and better returns on their investment.

The escalating demand for livestock products is driving increased utilization of anticoccidial drugs in the global market. As the need for protein-rich food sources continues to grow, the demand for effective disease control measures such as anticoccidial drugs is expected to remain strong, driving further growth and innovation in the global anticoccidial drugs market.

Rising Prevalence of Coccidiosis

The rising prevalence of coccidiosis is a significant driver behind the growth of the global anticoccidial drugs market. Coccidiosis is a parasitic disease caused by various species of the protozoan parasite Eimeria, affecting a wide range of livestock species including poultry, cattle, swine, and sheep. This disease poses a substantial threat to the livestock industry, leading to reduced productivity, increased morbidity and mortality rates, and significant economic losses for farmers.

Several factors contribute to the increasing prevalence of coccidiosis globally. Firstly, the intensification of livestock production practices, characterized by higher stocking densities and increased contact between animals, creates favorable conditions for the transmission and spread of coccidia. Additionally, factors such as poor sanitation, inadequate biosecurity measures, and the reuse of contaminated bedding or litter can further exacerbate the prevalence of the disease.

Climate change and environmental factors also play a role in the rising prevalence of coccidiosis. Changes in temperature and humidity can create optimal conditions for the survival and proliferation of coccidia oocysts in the environment, increasing the risk of infection for susceptible animals. Globalization and the movement of livestock and poultry across regions and borders have facilitated the spread of coccidia to previously unaffected areas, contributing to the expansion of the disease's geographical range.

The increasing prevalence of drug-resistant strains of coccidia is another factor driving the demand for anticoccidial drugs. Over time, repeated exposure to anticoccidial drugs can lead to the development of resistance in coccidia populations, rendering traditional treatment options less effective. As a result, there is a growing need for new and innovative anticoccidial drugs with novel modes of action to combat drug-resistant strains and provide effective control of the disease.

Technological Advancements in Drug Development

Technological advancements in drug development have significantly contributed to the growth and innovation within the global anticoccidial drugs market. These advancements encompass a wide range of scientific and technological breakthroughs, including novel drug formulations, improved delivery systems, and enhanced understanding of the biology and pathogenesis of coccidiosis. One of the key areas of advancement in anticoccidial drug development is the introduction of novel formulations with improved efficacy and safety profiles. Pharmaceutical companies are investing in research and development to identify new drug candidates and optimize existing compounds to enhance their effectiveness against coccidia. This includes the development of next-generation anticoccidial drugs that target specific stages of the parasite life cycle or exploit vulnerabilities in coccidia metabolism, leading to more targeted and efficient treatment options.

Furthermore, advancements in drug delivery systems have revolutionized the way anticoccidial drugs are administered to animals. Traditional methods of drug administration, such as oral medications or medicated feed, are being complemented by innovative delivery technologies such as injectable formulations, slow-release implants, and medicated water systems. These delivery systems offer greater convenience, precision, and control over drug dosing, ensuring optimal efficacy while minimizing the risk of under- or overdosing.

Biotechnology and genetic engineering have also played a significant role in advancing the field of anticoccidial drug development. Researchers are leveraging techniques such as recombinant DNA technology and gene editing to produce recombinant proteins, antibodies, and vaccines targeting coccidia parasites. These biotechnological approaches offer novel strategies for disease control and prevention, including the development of genetically modified organisms with enhanced resistance to coccidiosis or the production of recombinant vaccines capable of inducing protective immunity against multiple strains of coccidia.

Advancements in high-throughput screening, bioinformatics, and computational modeling have accelerated the process of drug discovery and development, enabling researchers to identify potential drug candidates more rapidly and cost-effectively. This has led to an increase in the number of new anticoccidial drugs entering the market and expanded the range of treatment options available to farmers and veterinarians.

Key Market Challenges

Regulatory Constraints

One of the significant challenges hindering the global anticoccidial drugs market is regulatory constraints imposed by governmental bodies and regulatory agencies. These regulations often vary across different regions and countries, creating complexities for manufacturers seeking to gain approval for their products. Stringent requirements for safety, efficacy, and quality assurance necessitate extensive preclinical and clinical testing, which can be time-consuming and costly. Additionally, concerns over antimicrobial resistance have prompted regulatory agencies to impose restrictions on the use of certain classes of antimicrobials, including anticoccidial drugs, further limiting the availability and usage of these products in some markets. Navigating the regulatory landscape requires significant resources and expertise, posing a barrier to entry for smaller pharmaceutical companies and hindering innovation within the market.

Concerns Over Antimicrobial Resistance

Another key challenge facing the global anticoccidial drugs market is the growing concern over antimicrobial resistance. Prolonged and widespread use of antimicrobial agents, including anticoccidial drugs, can contribute to the development of resistant strains of coccidia parasites, rendering traditional treatment options less effective. This not only undermines the efficacy of existing drugs but also poses a threat to animal health and welfare. Furthermore, antimicrobial resistance has broader implications for public health, as resistant pathogens can be transmitted from animals to humans through the food chain or environmental contamination. As a result, there is increasing pressure from consumers, policymakers, and regulatory agencies to promote the responsible use of antimicrobials in livestock production and to develop alternative strategies for disease control that minimize the risk of resistance development.

Emerging Alternatives to Anticoccidial Drugs

The emergence of alternative strategies for coccidiosis control presents a challenge to the global anticoccidial drugs market. Advances in biotechnology, immunology, and microbiology have led to the development of alternative approaches such as vaccines, probiotics, prebiotics, and plant-derived compounds for preventing and managing coccidiosis in livestock. These alternatives offer potential advantages such as reduced risk of antimicrobial resistance, improved animal welfare, and enhanced consumer acceptance. As a result, there is growing interest and investment in these alternative solutions, leading to increased competition for market share within the anticoccidial drugs market.

Key Market Trends

Expansion Of Intensive Farming Practices Worldwide

With the global population steadily increasing and dietary preferences shifting towards protein-rich diets, there is a growing demand for livestock products such as meat, dairy, and eggs. To meet this demand, farmers are increasingly adopting intensive farming methods, characterized by high stocking densities and confined housing systems.

Intensive farming practices also create ideal conditions for the transmission and spread of diseases like coccidiosis. Coccidia parasites thrive in warm, humid environments, making densely populated livestock facilities particularly susceptible to outbreaks. Coccidiosis can cause significant economic losses for farmers due to decreased productivity, increased mortality rates, and the cost of treatment and prevention measures.

As a result, there is a rising demand for effective disease control measures, including anticoccidial drugs, to safeguard animal health and productivity in intensive farming operations. Anticoccidial drugs play a crucial role in preventing and managing coccidiosis by controlling the growth and spread of coccidia parasites in infected animals. By minimizing the incidence and severity of the disease, these drugs help farmers maintain optimal growth rates, feed conversion ratios, and overall productivity in their livestock herds.

The intensification of livestock production has led to increased awareness among farmers about the importance of disease prevention and management. Farmers recognize the significant impact that diseases like coccidiosis can have on their bottom line and are therefore willing to invest in preventive measures to protect their animals and ensure profitability. Anticoccidial drugs are a key component of these disease management strategies, providing farmers with a reliable and cost-effective solution for controlling coccidiosis in their herds.

The expansion of intensive farming practices is driving innovation within the anticoccidial drugs market. Pharmaceutical companies are investing in research and development to introduce new and improved formulations with enhanced efficacy, safety profiles, and modes of action. These advancements in drug development are enabling farmers to achieve better disease control outcomes and improve the overall health and welfare of their animals.

Focus on Animal Health and Welfare

The global anticoccidial drugs market is witnessing a notable boost due to an increasing focus on animal health and welfare. As consumer awareness grows regarding the conditions in which livestock are raised and the impact of farming practices on animal well-being, there is a corresponding demand for products and practices that promote healthier, happier animals. This focus on animal welfare has led to significant changes within the agricultural industry, including a heightened emphasis on disease prevention and management.

Coccidiosis, caused by protozoan parasites of the genus Eimeria, poses a significant threat to animal health and productivity, particularly in intensive farming operations. Infected animals can suffer from reduced growth rates, decreased feed efficiency, and increased mortality rates, leading to economic losses for farmers. In response, there has been a growing recognition of the importance of implementing effective disease control measures, such as the use of anticoccidial drugs, to safeguard animal health and welfare.

Anticoccidial drugs play a crucial role in preventing and controlling coccidiosis in livestock populations. By controlling the growth and spread of coccidia parasites, these drugs help to minimize the incidence and severity of the disease, thereby improving animal well-being and productivity. Farmers and livestock producers recognize the importance of maintaining healthy animals not only for ethical reasons but also for economic sustainability.

The focus on animal health and welfare extends beyond individual farm practices to encompass broader societal concerns about antibiotic resistance and food safety. There is increasing pressure from consumers, policymakers, and regulatory agencies to reduce the use of antibiotics in livestock production and to adopt alternative disease management strategies that prioritize animal welfare and environmental sustainability. In this context, anticoccidial drugs offer a valuable solution for controlling coccidiosis while minimizing the use of antibiotics in animal agriculture. These drugs are an essential tool for farmers seeking to maintain high standards of animal health and welfare while meeting the growing demand for sustainably produced meat, dairy, and eggs.

Segmental Insights

Drug Class Insights

Based on the drug class, the other drug classes emerged as the dominant segment in the global anticoccidial drugs market in 2023. Synthetic drugs are preferred by farmers and veterinarians for their reliability and convenience in disease management. These drugs are available in various formulations, including oral medications, feed additives, and water-soluble powders, allowing for flexible administration options tailored to the specific needs of different livestock species and production environments. Synthetic drugs are often more cost-effective compared to alternative treatment options such as vaccines or natural remedies, making them a practical choice for disease control in commercial livestock operations.

Drug Action Insights

Based on drug action, Coccidiostatic emerged as the dominant segment in the global anticoccidial drugs market in 2023. This is due to their ability to suppress parasite growth without eliminating them entirely, potentially reducing the likelihood of resistance development. Coccidiostatic drugs may offer a more sustainable approach, allowing for prolonged use while maintaining efficacy. This could appeal to farmers seeking long-term solutions for managing coccidiosis in their livestock, thus driving demand for coccidiostatic drugs in the market.

Regional Insights

North America emerged as the dominant player in the global anticoccidial drugs market in 2023, holding the largest market share. The region boasts a large and highly developed livestock industry, particularly in sectors such as poultry and cattle production. The intensive farming practices prevalent in North America create ideal conditions for the transmission and spread of diseases like coccidiosis, driving the demand for effective disease control measures such as anticoccidial drugs.

Key Market Players

Vetoquinol SA

Zoetis Philippines Inc

Phibro Animal Health Corporation

Huvepharma, Inc

Elanco US Inc.

Biochem Pharmaceutical Industries Ltd

Ceva Sante Animale SA

Impextraco NV

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

Report Scope:

In this report, the Global Anticoccidial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticoccidial Drugs Market, By Drug Class:

Ionophore Antibiotic Sulphonamides Chemical Derivative Other Drug Classes

Anticoccidial Drugs Market, By Drug Action:

Coccidiostatic Coccidiocidal

Anticoccidial Drugs Market, By Animal Type:

Production Animals Companion Animals

Anticoccidial Drugs Market, By Distribution Channel:

Veterinary Hospitals Retail Pharmacy Other Distribution Channels

Anticoccidial Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anticoccidial Drugs Market.

Available Customizations:

Global Anticoccidial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Anticoccidial Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Ionophore, Antibiotic, Sulphonamides, Chemical Derivative, Other Drug Classes)
  • 5.2.2. By Drug Action (Coccidiostatic, Coccidiocidal)
  • 5.2.3. By Animal Type (Production Animals, Companion Animals)
  • 5.2.4. By Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Other Distribution Channels)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Drug Class
  • 5.3.2. By Drug Action
  • 5.3.3. By Animal Type
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. Asia Pacific Anticoccidial Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Drug Action
  • 6.2.3. By Animal Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Anticoccidial Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Drug Action
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Anticoccidial Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Drug Action
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Anticoccidial Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Drug Action
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Anticoccidial Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Drug Action
      • 6.3.4.2.3. By Animal Type
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Anticoccidial Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Drug Action
      • 6.3.5.2.3. By Animal Type
      • 6.3.5.2.4. By Distribution Channel

7. Europe Anticoccidial Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Drug Action
  • 7.2.3. By Animal Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Anticoccidial Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Drug Action
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Anticoccidial Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Drug Action
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Anticoccidial Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Drug Action
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Anticoccidial Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Drug Action
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Anticoccidial Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Drug Action
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By Distribution Channel

8. North America Anticoccidial Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Drug Action
  • 8.2.3. By Animal Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Anticoccidial Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Drug Action
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Anticoccidial Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Drug Action
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Anticoccidial Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By Distribution Channel

9. South America Anticoccidial Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Drug Action
  • 9.2.3. By Animal Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Anticoccidial Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Drug Action
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Anticoccidial Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Drug Action
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Anticoccidial Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Drug Action
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Anticoccidial Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Drug Action
  • 10.2.3. By Animal Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Anticoccidial Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Drug Action
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Anticoccidial Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Drug Action
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Anticoccidial Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Drug Action
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By Distribution Channel
  • 10.3.4. Egypt Anticoccidial Drugs Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Class
      • 10.3.4.2.2. By Drug Action
      • 10.3.4.2.3. By Animal Type
      • 10.3.4.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Anticoccidial Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Vetoquinol SA
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zoetis Philippines Inc
• 15.3. Phibro Animal Health Corporation
• 15.4. Huvepharma, Inc
• 15.5. Elanco US Inc.
• 15.6. Biochem Pharmaceutical Industries Ltd
• 15.7. Ceva Sante Animale SA
• 15.8. Impextraco NV
• 15.9. Boehringer Ingelheim International GmbH
• 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer